CINXE.COM
Advancing treatment options for rare disease patients
<!DOCTYPE html><html lang="en"><head><link rel="stylesheet" data-href="https://fonts.googleapis.com/css?family=Roboto+Slab%7COpen+Sans%7CRoboto&display=swap" data-optimized-fonts="true"/><title>Advancing treatment options for rare disease patients</title><link rel="icon" href="https://cdn.magloft.com/pwa-663/pwa/logo/3a135966-5949-4bdd-8a26-75e825872c5a.png"/><link rel="shortcut icon" type="image/x-icon" href="https://cdn.magloft.com/pwa-663/pwa/logo/3a135966-5949-4bdd-8a26-75e825872c5a.png?optimizer=image&format=webp&width=180&aspectRatio=1"/><link rel="apple-touch-icon" sizes="180x180" href="https://cdn.magloft.com/pwa-663/pwa/logo/3a135966-5949-4bdd-8a26-75e825872c5a.png?optimizer=image&format=webp&width=180&aspectRatio=1"/><link rel="canonical" href="/domains/magazine.pharmafile.com/articles/advancing-treatment-options-for-rare-disease-patients"/><meta name="application-name" content="Advancing treatment options for rare disease patients"/><meta name="apple-mobile-web-app-capable" content="yes"/><meta name="apple-mobile-web-app-status-bar-style" content="default"/><meta name="apple-mobile-web-app-title" content="Advancing treatment options for rare disease patients"/><meta name="format-detection" content="telephone=no"/><meta name="mobile-web-app-capable" content="yes"/><meta name="msapplication-TileColor" content="#1976D2"/><meta name="msapplication-tap-highlight" content="no"/><link rel="manifest" href="/manifest.json"/><meta name="twitter:url" content="https://magazine.pharmafile.com"/><meta name="theme-color" content="#1976D2"/><meta name="viewport" content="width=device-width, initial-scale=1"/><meta charSet="utf-8"/><meta itemProp="name" content="Advancing treatment options for rare disease patients"/><meta name="keywords" content="advancing treatment options for rare disease"/><meta itemProp="description" content="Chris moore from veeva europe explores how companies are overcoming challenges to develop, launch and educate on new rare disease medicines faster"/><meta name="description" content="Chris moore from veeva europe explores how companies are overcoming challenges to develop, launch and educate on new rare disease medicines faster"/><meta itemProp="image" content="https://cdn.magloft.com/pdf-import/1066/images/img_22-2.jpg"/><meta property="og:description" content="Chris moore from veeva europe explores how companies are overcoming challenges to develop, launch and educate on new rare disease medicines faster"/><meta property="og:title" content="Advancing treatment options for rare disease patients"/><meta property="og:site_name" content="Advancing treatment options for rare disease patients"/><meta property="og:image" content="https://cdn.magloft.com/pdf-import/1066/images/img_22-2.jpg"/><meta property="og:type" content="website"/><meta name="twitter:card" content="summary_large_image"/><meta name="twitter:title" content="Advancing treatment options for rare disease patients"/><meta name="twitter:description" content="Chris moore from veeva europe explores how companies are overcoming challenges to develop, launch and educate on new rare disease medicines faster"/><meta name="twitter:image" content="https://cdn.magloft.com/pdf-import/1066/images/img_22-2.jpg"/><meta name="author" content="Pharmafile"/><meta property="article:author" content="Pharmafile"/><meta property="article:published_time" content="2024-05-21T00:00:00.000Z"/><meta name="twitter:site" content="@pharmafocus"/><meta name="twitter:creator" content="@pharmafocus"/><style>html{--heading-font: "Roboto Slab";--body-font: "Open Sans";--ui-font: "Roboto";--top-menu-title-font: "Roboto Slab";--top-menu-subtitle-font: "Roboto";--top-menu-items-font: "Roboto";--footer-menu-title-font: "Roboto Slab";--footer-menu-items-font: "Roboto";--background-color: #FFFFFF;--background-color-dark: #808080;--primary-color: #1976D2;--primary-color-dark: #0C3B69;--secondary-color: #795FF4;--secondary-color-dark: #250B9F;--accent-color: #D76FD6;--accent-color-dark: #80237F;--info-color: #41638C;--info-color-dark: #213246;--warning-color: #EF9338;--warning-color-dark: #89490B;--success-color: #20AD27;--success-color-dark: #105714;--danger-color: #DF4241;--danger-color-dark: #7B1515;--top-menu-background-color: #FFFFFF;--top-menu-background-color-dark: #808080;--footer-menu-background-color: #000000;--footer-menu-background-color-dark: #000000;--top-menu-heading-title-color: #000000;--top-menu-heading-title-color-dark: #000000;--top-menu-item-text-color: #000000;--top-menu-item-text-color-dark: #000000;--top-menu-item-icon-color: #000000;--top-menu-item-icon-color-dark: #000000;--navbar-height: 64px; }</style><link rel="stylesheet" data-href="https://use.typekit.net/nat8xfl.css" data-optimized-fonts="true"/><script type="text/javascript" src="https://cdn.jsdelivr.net/npm/cookie-bar/cookiebar-latest.min.js?customize=1&always=1&showNoConsent=1"></script><meta name="google-site-verification" content="1Gr9skOzVfL3FXDYTam8oONdREeoeMCoQWnlojFJHX0"/><style> #billboard-banner { text-align:center;} #billboard-banner img {width:100%; max-width:970px; height:auto; position:relative; top:70px;} </style><meta name="next-head-count" content="43"/><link rel="preconnect" href="https://fonts.googleapis.com"/><link rel="preconnect" href="https://fonts.gstatic.com"/><link rel="preload" href="/_next/static/css/229efe2956472d85.css" as="style"/><link rel="stylesheet" href="/_next/static/css/229efe2956472d85.css" data-n-g=""/><link rel="preload" href="/_next/static/css/7c74bf24f71f6c9d.css" as="style"/><link rel="stylesheet" href="/_next/static/css/7c74bf24f71f6c9d.css" data-n-p=""/><link rel="preload" href="/_next/static/css/eaa0062c2481f7ca.css" as="style"/><link rel="stylesheet" href="/_next/static/css/eaa0062c2481f7ca.css" data-n-p=""/><noscript data-n-css=""></noscript><script defer="" nomodule="" src="/_next/static/chunks/polyfills-c67a75d1b6f99dc8.js"></script><script defer="" src="https://fonts.googleapis.com/css?family=Open+Sans&display=swap" data-nscript="beforeInteractive"></script><script src="/_next/static/chunks/webpack-b653c683a51d8b57.js" defer=""></script><script src="/_next/static/chunks/framework-73b8966a3c579ab0.js" defer=""></script><script src="/_next/static/chunks/main-34cb81d5753e1fc4.js" defer=""></script><script src="/_next/static/chunks/pages/_app-6805a2020fbcfa43.js" defer=""></script><script src="/_next/static/chunks/ad273671-3092333ffa02af02.js" defer=""></script><script src="/_next/static/chunks/876-c944523f292a2885.js" defer=""></script><script src="/_next/static/chunks/223-fe6833f316a5a95f.js" defer=""></script><script src="/_next/static/chunks/174-d95909d2aa5e8ec8.js" defer=""></script><script src="/_next/static/chunks/302-d0f1826200f9f2a4.js" defer=""></script><script src="/_next/static/chunks/pages/domains/%5Bdomain%5D/articles/%5Bslug%5D-12d0888066c7f18b.js" defer=""></script><script src="/_next/static/U1LT7ce93wR6IyWFJCllT/_buildManifest.js" defer=""></script><script src="/_next/static/U1LT7ce93wR6IyWFJCllT/_ssgManifest.js" defer=""></script><style data-styled="" data-styled-version="5.3.9"></style><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto+Slab%7COpen+Sans%7CRoboto&display=swap"/><link rel="stylesheet" href="https://use.typekit.net/nat8xfl.css"/></head><body><div id="__next"><div class="Layout_container__gktH6"><div class="Layout_navbar-container__gCfDZ" style="height:64px"><nav class="_wrapper_jbnbd_1"><div class="_container_jbnbd_15"><div class="_navbar-prefix_jbnbd_108"><div class="Layout_prefix__7W2Vq"><button><div class="_nav-arrow-left_1lm7t_183 _icon_1lm7t_1 icon"></div></button></div></div><a class="_navbar-brand_jbnbd_29" aria-label="Pharmafile" href="/"><div class="_navbar-image_jbnbd_40"><img alt="Logo" loading="lazy" decoding="async" data-nimg="fill" class="_image_jbnbd_43" style="position:absolute;height:100%;width:100%;left:0;top:0;right:0;bottom:0;color:transparent" sizes="100vw" srcSet="https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 54w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 70w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 82w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 96w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 110w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 128w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 138w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 192w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 200w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 252w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 260w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 298w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 378w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 384w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 520w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 640w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 756w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 828w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 1080w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 1200w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 1920w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 2048w" src="https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png"/></div><div class="_navbar-title_jbnbd_58 _navbar-title-hide_jbnbd_101"><span>Therapeutic areas in focus</span></div></a><div id="navbar-children-container" class="_navbar-children_jbnbd_116"><div class="_menu_1jhrl_1"><div class="_menu-wrapper_1jhrl_22"><div class="_menu-items_1jhrl_38"><a class="_menu-item_1jhrl_38" href="/"><div class="_menu-home_1lm7t_255 _menu-item-icon_1jhrl_97 _icon_1lm7t_1 icon"></div><div class="_menu-item-title_1jhrl_88">Home</div><div class="_indicator_1jhrl_63"></div></a><a class="_menu-item_1jhrl_38 _active_1jhrl_70" href="/articles"><div class="_menu-articles_1lm7t_259 _menu-item-icon_1jhrl_97 _icon_1lm7t_1 icon"></div><div class="_menu-item-title_1jhrl_88">Articles</div><div class="_indicator_1jhrl_63 _active_1jhrl_70"></div></a><a class="_menu-item_1jhrl_38" href="/collections"><div class="_menu-issues_1lm7t_263 _menu-item-icon_1jhrl_97 _icon_1lm7t_1 icon"></div><div class="_menu-item-title_1jhrl_88">Issues</div><div class="_indicator_1jhrl_63"></div></a><a class="_menu-item_1jhrl_38" href="/account/login"><div class="_menu-account_1lm7t_411 _menu-item-icon_1jhrl_97 _icon_1lm7t_1 icon"></div><div class="_menu-item-title_1jhrl_88">Log in</div><div class="_indicator_1jhrl_63"></div></a></div></div></div></div><div id="navbar-suffix" class="_navbar-suffix_jbnbd_108"><div class="Layout_menu-actions__vsDbI"><div class="Layout_install-button__FBfSr"><div class="Tooltip_tooltip__98Sw9"></div><button class="_button_19h3g_1 _text_19h3g_12 _medium_19h3g_38 _secondary_19h3g_22" type="button" style="color:var(--top-menu-item-icon-color, var(--background-color))" role="button" aria-label="Search" aria-labelledby="labeldiv" title="Search"><div class="_action-search_1lm7t_15 _icon-button_19h3g_19 _icon_1lm7t_1 icon" style="background-color:var(--top-menu-item-icon-color, var(--background-color))"></div></button></div></div></div></div></nav></div><div class="Layout_main__evUHx"><div class="Layout_spacer__qTBD3" style="height:64px"></div><div class=""><div class=""></div><div class=""><div id="print-article" class="_slug__article__BPEHu"><div class="Article-module_article__kO4b9"><div id="outer" data-widget="page-widget" style="background-color:#FFFFFF;padding:16px 0px 24px 0px;color:#000000;text-align:left;font-family:"Open Sans"" class="Widget-module_outer__PBh8P Page-module_outer__g0XXH"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%"><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:0px 24px 8px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p>RARE DISEASES</p></div></div><div id="outer" data-widget="heading-widget" style="background-color:transparent;padding:0px 24px 16px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Heading-module_container__uHf-4"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%"><h2><span style="font-family:"Roboto Slab"" class="__bold">Advancing treatment options for rare disease patients</span></h2></div></div><div id="outer" data-widget="paragraph-widget" style="background-color:rgba(202,45,42,1);padding:8px 24px 8px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p><span class="__bold" style="color:rgb(255, 254, 254)">Chris Moore from Veeva Europe explores how companies are overcoming challenges to develop, launch and educate on new rare disease medicines faster</span></p></div></div><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:16px 24px 8px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p><span class="__bold" style="color:rgb(38,37,35)">The landscape of rare diseases has evolved significantly and the number of people with a rare disease challenges the very notion of their rarity. Every year, thousands of individuals confront the life-altering reality of being diagnosed with one of the 6,000-8,000 identified rare conditions, collectively affecting one in 17 individuals.<span class="__superscript">1</span> The majority of these conditions are genetic and emerge early in life, with more than half of patients being children, many of whom are not expected to reach their fifth birthday. </span></p></div></div><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:0px 24px 8px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p>Less than 5% of rare diseases have even a single approved treatment today.<span class="__superscript" style="color:rgb(38,37,35)">2 </span>Finding new treatments is an urgent challenge, especially for patients left waiting for medical advancements. Survey findings underscore the long and emotionally taxing journey endured by individuals awaiting a diagnosis. Among adults, a rare disease diagnosis can take up to five years, with half receiving a misdiagnosis. The need for increased awareness, research and expedited treatment pathways in rare disease remains critical.</p></div></div><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:0px 24px 8px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p>Rare diseases challenge traditional ways of doing business. They require the industry to better identify target patient populations for trials and then keep them engaged during the course of the study, even across geographies. Once a medicine is approved, it is crucial to seamlessly transition from trials to treatment given the smaller patient cohort, as the physicians who conduct the trials often become prescribers.</p></div></div><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:0px 24px 8px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p>The good news is that the industry is making great progress in how medicines for rare diseases are developed and brought to market. From delivering better site support during clinical studies to greater connectivity between medical and commercial teams, companies are breaking down historic silos and cutting the time to treatment. Along with richer healthcare data and effective medical education for physicians on symptoms and treatment options, these advances will help those undergoing complex patient journeys.</p></div></div><div id="outer" data-widget="image-widget" style="background-color:transparent;padding:8px 24px 16px 24px;min-height:auto" class="Widget-module_outer__PBh8P"><div id="inner" class="Image-module_container__8raIv Image-module_container-noflex__-J1PG" style="border-radius:0px 0px 0px 0px;width:100%;min-height:auto"><picture class="Image-module_picture__gw1zY Image-module_loading__FfyPr"><source type="image/jpeg" srcSet="https://cdn.magloft.com/pdf-import/1066/images/img_22-2.jpg?optimizer=image&width=192 192w,https://cdn.magloft.com/pdf-import/1066/images/img_22-2.jpg?optimizer=image&width=384 384w,https://cdn.magloft.com/pdf-import/1066/images/img_22-2.jpg?optimizer=image&width=768 768w,https://cdn.magloft.com/pdf-import/1066/images/img_22-2.jpg?optimizer=image&width=1536 1536w" sizes="(min-width: 768px) 768px, 100vw"/><img src="https://cdn.magloft.com/pdf-import/1066/images/img_22-2.jpg?optimizer=image&width=768" srcSet="https://cdn.magloft.com/pdf-import/1066/images/img_22-2.jpg?optimizer=image&width=192 192w,https://cdn.magloft.com/pdf-import/1066/images/img_22-2.jpg?optimizer=image&width=384 384w,https://cdn.magloft.com/pdf-import/1066/images/img_22-2.jpg?optimizer=image&width=768 768w,https://cdn.magloft.com/pdf-import/1066/images/img_22-2.jpg?optimizer=image&width=1536 1536w" sizes="(min-width: 768px) 768px, 100vw" class="Image-module_image__w4slc" width="100%" height="575" decoding="async" alt="Image" style="height:auto;width:100%"/></picture></div></div><div id="outer" data-widget="heading-widget" style="background-color:transparent;padding:0px 24px 16px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Heading-module_container__uHf-4"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%"><h3><span class="__bold" style="color:rgb(38,37,35)">Putting the patient experience first during studies </span></h3></div></div><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:0px 24px 8px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p>Over half of orphan drug trials are eventually discontinued or fail to publish results after completion. Often, studies can’t recruit or lead to inconclusive results. When a trial gets off the ground, sites have to invest significant time in keeping a small number of participants engaged. Removing excessive system and process complexity will improve their efforts. For years, sites have voiced their concerns about the multiple disconnected tools they must navigate just to keep a study going. As one site leader explains, navigating unintuitive technology absorbs time from trial activities and can make them feel like they’re asking too much from patients: “The technology shouldn’t be the trial itself, it should support the trial. It’s taking time away from what we want to do, which is taking care of our patients.” Simplifying the technology experience and reducing the admin burden will better meet sites’ and patients’ needs.</p></div></div><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:0px 24px 8px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p>The knock-on effects could include better participant retention during rare disease trials. This may widen patient access to life-enhancing new treatments. Reflecting on her own experiences as a rare disease patient, Helen Shaw, co-founder of the virtual site VCTC, observes: “I see how hard it is to take part in a clinical trial. But patients do want that opportunity to be offered something that they wouldn’t get in their standard care, whether additional MRIs or new medicines.”</p></div></div><div id="outer" data-widget="heading-widget" style="background-color:transparent;padding:0px 24px 16px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Heading-module_container__uHf-4"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%"><h3><span class="__bold" style="color:rgb(38,37,35)">Data insights for effective commercial execution </span></h3></div></div><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:0px 24px 8px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p>Data is core to understanding where the greatest patient needs are ahead of a launch. ADVANZ PHARMA is a global biopharma company focused on specialty, hospital and rare disease medicines. Andy Eeckhout, head of CRM and digital solutions for global commercial excellence, explains: “It’s crucial to take a patient perspective. This means using real-time data to understand the patient journey and identify the two or three most influential key opinion leaders (KOLs) per country, so we can best communicate the product across markets.”</p></div></div><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:0px 24px 8px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p>An added complexity is that rare diseases often involve multiple specialties. Medical science liaison (MSL) teams have to get up to speed quickly on complex science before meetings with relevant experts, while also being responsible for other (more mainstream) disease areas. “Our customerfacing teams need to be agile communicators and effectively switch to a more patientoriented, in-depth scientific discussion than with generics,” Eeckhout explains. Access to scientific resources and activity data in one place leads to higher-quality conversations. “Pre-call planning is crucial for MSLs before and after launch. The more data they can find, including on past interactions, the better,” Eeckhout adds.</p></div></div><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:0px 24px 8px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p>Depending on the disease, there could be a long gap before a patient presents with potential symptoms, at which point HCPs will want timely access to experts and resources. Smoother handovers between field medical and sales ensure HCPs can find answers quickly and connect to MSLs if needed. ADVANZ, for example, has launched a pre-launch module in its CRM so that market access, medical and commercial teams can share information compliantly and effectively. Eeckhout notes: “Physicians need a direct line to the industry so they know who to contact when they have questions. Medical and commercial teams need to talk to each other and remain agile across customer conversations.”</p></div></div><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:0px 24px 8px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p>Highly personalised content for HCPs is also key when targeting diseases with small patient populations. To be effective, marketing teams need clarity on the most impactful content to recommend for field visits across markets. For example, Recordati Rare Disease uses data analytics on its global repository of promotional and medical engagement tools, so it can support content use across a portfolio of 17 rare disease medicines of focus (and a growing global footprint). As its head of marketing and customer engagement, Gordon Daniels, notes: “How we engage with HCPs is critical. We need to know what percentage of our content is being developed and relevant to support different HCPs, whose patients rely on them for their rare disease diagnosis and management.”</p></div></div><div id="outer" data-widget="heading-widget" style="background-color:transparent;padding:0px 24px 16px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Heading-module_container__uHf-4"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%"><h3><span class="__bold" style="color:rgb(38,37,35)">Defying the odds, and beating them </span></h3></div></div><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:0px 24px 8px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p>Many scientific advancements are offering hope to rare disease patients and their families. Organisations embarking on this long and sometimes risky trial-to-treatment pathway are making all the difference.</p></div></div><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:0px 24px 8px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p>Companies are actively shortening the time to treatment through better support for research sites. This support enables them to concentrate on patient recruitment and retention during trials. Once a drug is approved, integrated technology and comprehensive data can facilitate collaboration between traditionally siloed function. This collaboration allows for the identification, engagement and provision of medical education to relevant HCPs and KOLs.</p></div></div><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:0px 24px 8px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p>A multifaceted approach is also needed to tackle the diagnostic hurdles faced by patients with rare diseases. This includes raising awareness among healthcare professionals about the signs and symptoms of rare conditions, promoting the use of advanced diagnostic technologies such as genetic testing and molecular imaging and streamlining the referral process for patients suspected of having a rare disease.</p></div></div><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:0px 24px 8px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p>Efforts can be made to improve access to specialised healthcare services and expertise, particularly in underserved regions where diagnostic and treatment facilities may be limited. Making use of digital platforms can play a pivotal role in connecting patients with rare diseases to specialists, thereby overcoming geographical barriers and facilitating timely diagnosis and intervention.</p></div></div><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:0px 24px 16px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p>The journey for every rare disease patient can be a daunting one, with numerous challenges and hurdles they must face. As one biotech leader points out: “Their diagnosis is with them every day. Often, they can’t pronounce the condition, and don’t know anyone else who has it.” It’s up to the life sciences industry to do its part and to help these patients to not just defy the odds, but eventually beat them.</p></div></div><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:0px 24px 24px 24px;text-align:left;font-size:80%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p><span class="__italic">References</span><br/><ol><li><span class="__italic">Visit: <a class="__link" target="_self" href="https://eurordis.org/information-support/what-is-a-rare-disease/">eurordis.org/information-support/what-is-a-rare-disease/</a></span></li><li><span class="__italic">Visit: <a class="__link" target="_self" href="https://projects.research-and-innovation.ec.europa.eu/en/horizon-magazine/building-blocks-make-rare-diseasetreatments-more-common">projects.research-and-innovation.ec.europa.eu/en/horizon-magazine/building-blocks-make-rare-diseasetreatments-more-common</a></span></li></ol></p></div></div><div id="outer" data-widget="container-widget" style="background-color:transparent;padding:0px 24px 0px 24px;min-height:auto" class="Widget-module_outer__PBh8P Container-module_outer__Ae8eB"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%"><div id="outer" data-widget="horizontal-rule-widget" style="background-color:transparent;padding:0px 0px 0px 0px" class="Widget-module_outer__PBh8P HorizontalRule-module_outer__3UqSE"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%"><hr style="border-top-style:solid;border-top-width:6px;border-top-color:#f80202"/></div></div><div id="outer" data-widget="columns-widget" style="background-color:transparent;padding:0px 0px 0px 0px" class="Widget-module_outer__PBh8P"><div id="inner" class="Columns-module_inner__KeVpm Columns-module_collapse-phone__abOHb" style="border-radius:0px 0px 0px 0px;width:100%"><div class="Columns-module_column__hw-5a" style="margin:0px 12px;flex:4"><div id="outer" data-widget="column-widget" style="background-color:transparent;padding:0px 0px 0px 0px" class="Widget-module_outer__PBh8P Column-module_outer__vEJ6X"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%"><div id="outer" data-widget="image-widget" style="background-color:transparent;padding:8px 0px 16px 0px;min-height:auto" class="Widget-module_outer__PBh8P"><div id="inner" class="Image-module_container__8raIv Image-module_container-noflex__-J1PG" style="border-radius:0px 0px 0px 0px;width:100%;min-height:auto"><picture class="Image-module_picture__gw1zY Image-module_loading__FfyPr"><source type="image/jpeg" srcSet="https://cdn.magloft.com/pdf-import/1066/images/img_23-1.jpg?optimizer=image&width=192 192w,https://cdn.magloft.com/pdf-import/1066/images/img_23-1.jpg?optimizer=image&width=384 384w,https://cdn.magloft.com/pdf-import/1066/images/img_23-1.jpg?optimizer=image&width=768 768w,https://cdn.magloft.com/pdf-import/1066/images/img_23-1.jpg?optimizer=image&width=1536 1536w" sizes="(min-width: 768px) 768px, 100vw"/><img src="https://cdn.magloft.com/pdf-import/1066/images/img_23-1.jpg?optimizer=image&width=768" srcSet="https://cdn.magloft.com/pdf-import/1066/images/img_23-1.jpg?optimizer=image&width=192 192w,https://cdn.magloft.com/pdf-import/1066/images/img_23-1.jpg?optimizer=image&width=384 384w,https://cdn.magloft.com/pdf-import/1066/images/img_23-1.jpg?optimizer=image&width=768 768w,https://cdn.magloft.com/pdf-import/1066/images/img_23-1.jpg?optimizer=image&width=1536 1536w" sizes="(min-width: 768px) 768px, 100vw" class="Image-module_image__w4slc" width="100%" height="826" decoding="async" alt="Image" style="height:auto;width:100%"/></picture></div></div></div></div></div><div class="Columns-module_column__hw-5a" style="margin:0px 12px;flex:8"><div id="outer" data-widget="column-widget" style="background-color:transparent;padding:0px 0px 0px 0px" class="Widget-module_outer__PBh8P Column-module_outer__vEJ6X"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%"><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:8px 0px 8px 0px;text-align:left;font-size:80%;line-height:1.5;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p>As president of <span class="__bold">Veeva Europe</span>, <span class="__bold">Chris Moore</span> is responsible for growing the business in the region. A 30+ year veteran of the life sciences industry, Chris started his career at ICI Pharmaceuticals (now AstraZeneca). Chris then joined a startup called Kinesis, building a team delivering document management solutions for pharmaceutical companies. Through a series of mergers and acquisitions, Kinesis ultimately became PwC; Chris was made a partner with PwC in 2001. Chris went on to run both European and US (West Coast) life sciences businesses for IBM before leading the IBM global life sciences consulting Business Analytics and Optimisation unit. Most recently, Chris was the lead partner for life sciences for Europe, the Middle East and Africa at EY. Chris holds a bachelor of science degree in information technology from the University of Salford, UK.</p></div></div></div></div></div></div></div><div id="outer" data-widget="horizontal-rule-widget" style="background-color:transparent;padding:0px 0px 0px 0px" class="Widget-module_outer__PBh8P HorizontalRule-module_outer__3UqSE"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%"><hr style="border-top-style:solid;border-top-width:6px;border-top-color:#f80202"/></div></div></div></div></div></div></div><div class="_slug__share-button__ettip"><hr/></div></div></div><div id="ControlBar" class="_slug__control-bar__Jj4LE"><div class="WrapAutoHide-module_navigation__9sdQy WrapAutoHide-module_visible__UN7GD"><div class="ControlBar-module_toc-wrapper__AF5eD"><div class="ControlBar-module_toc__mKXnp"><div class="ControlBar-module_white-blur__TGapK"><div class="ControlBar-module_toc-slider__i9fv1"></div></div><div class="ControlBar-module_control-bar__9Zqak"><button class=""><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none"><path d="M13.8287 19C13.5367 19 13.2467 18.873 13.0487 18.627L8.22066 12.627C7.92266 12.256 7.92666 11.726 8.23166 11.36L13.2317 5.35998C13.5847 4.93598 14.2157 4.87898 14.6407 5.23198C15.0647 5.58498 15.1217 6.21598 14.7677 6.63998L10.2927 12.011L14.6077 17.373C14.9537 17.803 14.8857 18.433 14.4547 18.779C14.2707 18.928 14.0487 19 13.8287 19Z" fill="white"></path></svg></button><button class=""><svg xmlns="http://www.w3.org/2000/svg" width="18" height="14" viewBox="0 0 18 14" fill="none"><path d="M6.75 0H1.125C0.503719 0 0 0.503719 0 1.125V4.5C0 5.12128 0.503719 5.625 1.125 5.625C1.74628 5.625 2.25 5.12128 2.25 4.5V2.25H6.75C7.37128 2.25 7.875 1.74628 7.875 1.125C7.875 0.503719 7.37128 0 6.75 0Z" fill="white"></path><path d="M16.875 0H11.25C10.6287 0 10.125 0.503719 10.125 1.125C10.125 1.74628 10.6287 2.25 11.25 2.25H15.75V4.5C15.75 5.12128 16.2537 5.625 16.875 5.625C17.4963 5.625 18 5.12128 18 4.5V1.125C18 0.503719 17.4963 0 16.875 0Z" fill="white"></path><path d="M16.875 7.875C16.2537 7.875 15.75 8.37872 15.75 9V11.25H11.25C10.6287 11.25 10.125 11.7537 10.125 12.375C10.125 12.9963 10.6287 13.5 11.25 13.5H16.875C17.4963 13.5 18 12.9963 18 12.375V9C18 8.37872 17.4963 7.875 16.875 7.875Z" fill="white"></path><path d="M6.75 11.25H2.25V9C2.25 8.37872 1.74628 7.875 1.125 7.875C0.503719 7.875 0 8.37872 0 9V12.375C0 12.9963 0.503719 13.5 1.125 13.5H6.75C7.37128 13.5 7.875 12.9963 7.875 12.375C7.875 11.7537 7.37128 11.25 6.75 11.25Z" fill="white"></path></svg></button><button class="" disabled=""><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none"><g opacity="0.25"><path d="M9.9995 19C9.7735 19 9.5465 18.924 9.3595 18.768C8.9355 18.415 8.8785 17.784 9.2315 17.36L13.7075 11.989L9.3925 6.62701C9.0465 6.19701 9.1145 5.56701 9.5445 5.22101C9.9755 4.87501 10.6045 4.94301 10.9515 5.37301L15.7795 11.373C16.0775 11.744 16.0735 12.274 15.7685 12.64L10.7685 18.64C10.5705 18.877 10.2865 19 9.9995 19Z" fill="white"></path></g></svg></button></div></div></div></div></div><div class="_slug__wrapper__0ZIJf"></div><div></div></div></div><script> //create a new element const terms = document.createElement('div'); //set id terms.setAttribute("id","billboard-banner"); //add the new element to html var body = document.querySelector('body'); body.appendChild(terms); document.querySelector("#billboard-banner").innerHTML = "<ins data-revive-zoneid='1569' data-revive-id='9c421b7e485bf2edfee09708a4d06e2e'></ins>"; //insert new element before header //document.body.insertAdjacentElement('afterbegin', terms); const insElement = document.querySelector("#__next"); insElement.before(terms); </script> <script async="" src="//ads.datateam.co.uk/www/delivery/asyncjs.php"></script><div class="_footer_j8nu5_1"><div class="_container_j8nu5_12"><div class="_footer-row_j8nu5_23"><div class="_footer-column_j8nu5_36 _flex-2_j8nu5_117"><div class="_footer-brand_j8nu5_43"><div class=""><img alt="Logo" loading="lazy" width="40" height="40" decoding="async" data-nimg="1" class="_footer-logo_j8nu5_57" style="color:transparent" srcSet="https://media.magloft.app/pwa-663/pwa/footer-menu-icon/b422c56e-036d-422f-96b0-a6c3d151026b.png 1x, https://media.magloft.app/pwa-663/pwa/footer-menu-icon/b422c56e-036d-422f-96b0-a6c3d151026b.png 2x" src="https://media.magloft.app/pwa-663/pwa/footer-menu-icon/b422c56e-036d-422f-96b0-a6c3d151026b.png"/></div><div class="_content_j8nu5_67"><h3>Pharmafile</h3><p>Therapeutic areas in focus</p></div></div><div class="_footer-link-list_j8nu5_121"><div class="_block_j8nu5_129"><a class="_footer-link-item_j8nu5_92" rel="noreferrer" href="mailto:info@samedanltd.com"><div class="_form-email_1lm7t_143 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div><span>info@samedanltd.com</span></a></div><div class="_block_j8nu5_129"><a class="_footer-link-item_j8nu5_92" target="_blank" rel="noreferrer" href="https://pwa.magloft.com/"><div class="_status-info_1lm7t_87 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div><span>www.samedanltd.com</span></a></div><a target="_blank" rel="noreferrer" class="_footer-link-item_j8nu5_92" href="http://www.samedanltd.com/page/13"><div class="_status-info_1lm7t_87 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div><span>Privacy Policy</span></a><a target="_blank" rel="noreferrer" class="_footer-link-item_j8nu5_92" href="http://www.samedanltd.com/page/13"><div class="_status-info_1lm7t_87 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div><span>Terms of Service</span></a></div></div><div class="_footer-column_j8nu5_36 _flex-1_j8nu5_39"><div class="_footer-brand_j8nu5_43"><div class="_status-accent_1lm7t_91 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div><div class="_content_j8nu5_67"><h3>Categories</h3><p>Explore our inspiring content by topic</p></div></div><div class="_footer-link-list_j8nu5_121"><a class="_footer-link-item_j8nu5_92" href="/categories/infectious-diseases"><div class="_nav-arrow-right_1lm7t_175 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div>Infectious Diseases</a><a class="_footer-link-item_j8nu5_92" href="/categories/rare-diseases"><div class="_nav-arrow-right_1lm7t_175 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div>Rare Diseases</a><a class="_footer-link-item_j8nu5_92" href="/categories/dermatology"><div class="_nav-arrow-right_1lm7t_175 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div>Dermatology</a><a class="_footer-link-item_j8nu5_92" href="/categories/oncology"><div class="_nav-arrow-right_1lm7t_175 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div>Oncology</a><a class="_footer-link-item_j8nu5_92" href="/categories/respiratory"><div class="_nav-arrow-right_1lm7t_175 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div>Respiratory</a><a class="_footer-link-item_j8nu5_92" href="/categories/pain"><div class="_nav-arrow-right_1lm7t_175 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div>Pain</a><a class="_footer-link-item_j8nu5_92" href="/categories/neurology"><div class="_nav-arrow-right_1lm7t_175 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div>Neurology</a><a class="_footer-link-item_j8nu5_92" href="/categories/cardiovascular"><div class="_nav-arrow-right_1lm7t_175 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div>Cardiovascular</a><a class="_footer-link-item_j8nu5_92" href="/categories/womens-health"><div class="_nav-arrow-right_1lm7t_175 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div>Women's Health</a><a class="_footer-link-item_j8nu5_92" href="/categories/news"><div class="_nav-arrow-right_1lm7t_175 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div>News</a></div></div><div class="_footer-column_j8nu5_36 _flex-1_j8nu5_39"><div class="_footer-brand_j8nu5_43"><div class="_share-action_1lm7t_463 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div><div class="_content_j8nu5_67"><h3>Social Footprints</h3><p>Follow us on our Social Media Channels</p></div></div><div class="_footer-link-list_j8nu5_121"><a class="_footer-link-item_j8nu5_92" target="_blank" rel="noreferrer" href="https://twitter.com/pharmafocus"><div class="_share-twitter_1lm7t_487 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div><span class="_footer-text_j8nu5_125">X</span></a><a class="_footer-link-item_j8nu5_92" target="_blank" rel="noreferrer" href="https://www.linkedin.com/company/samedan-ltd/"><div class="_share-linkedin_1lm7t_483 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div><span class="_footer-text_j8nu5_125">linkedin</span></a></div></div></div></div></div></div><div class="Toastify"></div></div><script id="__NEXT_DATA__" type="application/json">{"props":{"pageProps":{"domain":"magazine.pharmafile.com","pwa":{"id":663,"publicationId":14881,"pwaOptinId":655,"domain":"magazine.pharmafile.com","config":{"access":{"concurrentLimit":null,"restrictAnonymous":null,"disableSignup":null,"disableLogin":null,"disableLoginMessage":null,"disableSearchIndexing":false,"signupUrl":null,"resetPasswordUrl":null,"isUsernameLogin":null,"disableEditProfile":null,"formUrl":null,"customMarginResetPassword":null},"push":{"google":{"serverPublicKey":"BM0A-3PI9oRiVvVNuci8EbmGIC655KFzdqh9tQxnt5n6T-oECeS2hReTgrjYtIeeK0wsWfMB6VixaHT_RxZ15J0"}},"tracking":{"facebook":{"appId":null,"pixelId":null},"google":{"measurementId":"G-L1MVP1ECDJ"},"gtm":null,"sentry":true},"payment":{"stripe":null,"bypassPayment":null,"mode":"none","external":null,"currency":null},"email":{"readerOptin":false},"firebase":null,"customHtml":{"head":"\u003clink rel=\"stylesheet\" href=\"https://use.typekit.net/nat8xfl.css\"\u003e\n\u003cscript type=\"text/javascript\" src=\"https://cdn.jsdelivr.net/npm/cookie-bar/cookiebar-latest.min.js?customize=1\u0026always=1\u0026showNoConsent=1\" onload=\"setupCookieBar();\"\u003e\u003c/script\u003e\n\u003c!-- Google Search console Verification --\u003e\n\u003cmeta name=\"google-site-verification\" content=\"1Gr9skOzVfL3FXDYTam8oONdREeoeMCoQWnlojFJHX0\" /\u003e\n\u003cstyle\u003e\n#billboard-banner { text-align:center;}\n#billboard-banner img {width:100%; max-width:970px; height:auto; position:relative; top:70px;}\n\u003c/style\u003e","body":"\u003cscript\u003e\n //create a new element\n const terms = document.createElement('div');\n //set id\n terms.setAttribute(\"id\",\"billboard-banner\");\n //add the new element to html\n var body = document.querySelector('body');\n body.appendChild(terms);\n document.querySelector(\"#billboard-banner\").innerHTML = \"\u003cins data-revive-zoneid='1569' data-revive-id='9c421b7e485bf2edfee09708a4d06e2e'\u003e\u003c/ins\u003e\"; \n //insert new element before header\n//document.body.insertAdjacentElement('afterbegin', terms);\n const insElement = document.querySelector(\"#__next\");\n insElement.before(terms);\n\u003c/script\u003e\n\u003cscript async src=\"//ads.datateam.co.uk/www/delivery/asyncjs.php\"\u003e\u003c/script\u003e"},"account":{"emailEditable":true,"customSubscriptionText":null,"customSubscriptionURL":null,"enableSubscriptionTitle":null},"checkout":null},"design":{"colors":{"backgroundColor":"#FFFFFF","primaryColor":"#1976D2","secondaryColor":"#795FF4","accentColor":"#D76FD6","infoColor":"#41638C","warningColor":"#EF9338","successColor":"#20AD27","dangerColor":"#DF4241","topMenuBackgroundColor":"#FFFFFF","topMenuHeadingTitleColor":"#000000","topMenuHeadingIconColor":null,"topMenuItemTextColor":"#000000","topMenuItemIconColor":"#000000","footerMenuBackgroundColor":"#000000","footerMenuHeadingTitleColor":null,"footerMenuHeadingTextColor":null,"footerMenuHeadingIconColor":null,"footerMenuItemTextColor":null,"footerMenuItemIconColor":null},"images":{"icon":"https://cdn.magloft.com/pwa-663/pwa/logo/3a135966-5949-4bdd-8a26-75e825872c5a.png","feature":"https://cdn.magloft.com/defaults/feature-graphic.jpg","topMenuIcon":"https://cdn.magloft.com/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png","footerMenuIcon":"https://cdn.magloft.com/pwa-663/pwa/footer-menu-icon/b422c56e-036d-422f-96b0-a6c3d151026b.png","alphaChannelIcon":null},"fonts":{"heading":"roboto-slab","body":"open-sans","ui":"roboto","topMenuTitle":"roboto-slab","topMenuItems":null,"topMenuSubtitle":null,"footerMenuTitle":"roboto-slab","footerMenuItems":null},"menuItems":{"collections":{"title":"Issues"},"articles":{"title":null},"account":{"title":null},"icons":{"enabled":true}},"footerShape":"flat","issueCoverAspectRatio":0.75,"fullscreenCollectionView":"auto","customOverlayToggleView":false,"defaultViewMode":"html","categories":"flat","purchaseList":true,"libraryList":false,"noteList":false,"textToSpeech":false},"layout":{"banners":[{"image":"https://cdn.magloft.com/pwa-663/pwa/banner/994f2837-a9d2-437b-92bc-e0b130e07bf6.png","title":"Pharmafile Magazine","isHidden":true,"action":{"type":"url","href":"https://www.pharmafile.com/","target":"_blank","pwaSubscriptionId":null,"pwaSubscription":null,"optinId":null,"optin":null}}],"bottomBanners":[{"image":"https://cdn.magloft.com/pwa-663/pwa/banner/f3f87ce8-ef8e-4547-b63f-f4805a25e350.png","title":"Samedan","isHidden":false,"action":{"type":"url","href":"http://www.samedanltd.com/","target":"_blank","pwaSubscriptionId":null,"pwaSubscription":null,"optinId":null,"optin":null}}],"columnSeparator":"shadow","tabs":[{"route":"","title":"Home","icon":"menu-home","visible":true},{"route":"/articles","title":"Articles","icon":"menu-articles","visible":true},{"route":"/collections","title":"Collections","icon":"menu-issues","visible":true},{"route":"/account","title":"Account","icon":"menu-account","visible":true}],"topMenu":{"showLogo":true,"showSubtitle":true,"showTitle":false,"height":"64px"},"navbar":{"animation":false,"style":"logo-left"},"sections":[{"fullWidth":true,"backgroundColor":"transparent","columnSeparator":"none","columns":[{"size":5,"blocks":[{"type":"banner","image":"https://cdn.magloft.com/pwa-663/pwa/banner/994f2837-a9d2-437b-92bc-e0b130e07bf6.png","isHidden":true,"title":"Pharmafile Magazine","action":{"type":"url","href":"https://www.pharmafile.com/","target":"_blank","pwaSubscriptionId":null,"pwaSubscription":null,"optinId":null,"optin":null}}]}]},{"fullWidth":false,"backgroundColor":null,"columnSeparator":"shadow","columns":[{"size":8.5,"blocks":[{"type":"issue-slider","condition":null,"color":"#F50D0D","title":"Latest Issues","issueIds":[51652,50092,47546,47328],"thumbnail":{"style":"overlay","size":"tall"},"borderRadius":null,"zoomOnHover":true,"issues":null},{"type":"article-list","condition":null,"color":"#000000","title":"Trending","variant":"variant-b","articleIds":[258239,258236,258240,258242,258238,258237],"articles":null},{"type":"article-category","condition":null,"color":"#F50D0D","title":"Rare Diseases","variant":"variant-b","categoryId":42211,"backgroundColor":null,"image":"https://cdn.magloft.com/pwa-663/category/image/62a51415-ed19-4d78-8601-68087122c29b.jpg","articles":null,"category":null},{"type":"article-category","condition":null,"color":"#E2001A","title":"Infectious Diseases","variant":"variant-a","categoryId":42331,"backgroundColor":null,"image":"https://cdn.magloft.com/pwa-663/category/image/253ea686-a135-4a29-b1a2-f8a0b400a4f5.jpg","articles":null,"category":null},{"type":"article-category","condition":null,"color":"#E2001A","title":"Dermatology","variant":"variant-a","categoryId":42212,"backgroundColor":null,"image":null,"articles":null,"category":null},{"type":"article-list","condition":null,"color":"#195AA6","title":"Pain","variant":"variant-a","articleIds":[183367,183366,183365],"articles":null}]},{"size":3.5,"blocks":[{"type":"cta","condition":null,"icon":"symbol-bell","color":"#195AA6","title":"Pharmafile Archive","description":"Browse older editions","action":{"type":"url","href":"https://en.calameo.com/subscriptions/6188509","target":"_blank","pwaSubscriptionId":null,"pwaSubscription":null,"optinId":null,"optin":null}},{"type":"ad","title":"Advertisement","advertisementIds":[1974],"adCampaignId":null,"condition":null},{"type":"cta","condition":null,"icon":"symbol-bell","color":"#195AA6","title":"Sign up to our Newsletters","description":"Sign up to our newsletters and digital magazines","action":{"type":"url","href":"https://curwoodcmsltd.formstack.com/forms/samedan","target":"_blank","pwaSubscriptionId":null,"pwaSubscription":null,"optinId":null,"optin":null}},{"type":"guide-install","color":"#195AA6","title":"How to Install","condition":null},{"type":"ad","title":"Advertisement","advertisementIds":[2235],"adCampaignId":null,"condition":null}]}]},{"fullWidth":true,"backgroundColor":"transparent","columnSeparator":"none","columns":[{"size":5,"blocks":[{"type":"banner","image":"https://cdn.magloft.com/pwa-663/pwa/banner/f3f87ce8-ef8e-4547-b63f-f4805a25e350.png","isHidden":false,"title":"Samedan","action":{"type":"url","href":"http://www.samedanltd.com/","target":"_blank","pwaSubscriptionId":null,"pwaSubscription":null,"optinId":null,"optin":null}}]}]}],"columns":[{"size":8.5,"blocks":[{"type":"issue-slider","condition":null,"color":"#F50D0D","title":"Latest Issues","issueIds":[51652,50092,47546,47328],"thumbnail":{"style":"overlay","size":"tall"},"borderRadius":null,"zoomOnHover":true,"issues":null},{"type":"article-list","condition":null,"color":"#000000","title":"Trending","variant":"variant-b","articleIds":[258239,258236,258240,258242,258238,258237],"articles":null},{"type":"article-category","condition":null,"color":"#F50D0D","title":"Rare Diseases","variant":"variant-b","categoryId":42211,"backgroundColor":null,"image":"https://cdn.magloft.com/pwa-663/category/image/62a51415-ed19-4d78-8601-68087122c29b.jpg","articles":null,"category":null},{"type":"article-category","condition":null,"color":"#E2001A","title":"Infectious Diseases","variant":"variant-a","categoryId":42331,"backgroundColor":null,"image":"https://cdn.magloft.com/pwa-663/category/image/253ea686-a135-4a29-b1a2-f8a0b400a4f5.jpg","articles":null,"category":null},{"type":"article-category","condition":null,"color":"#E2001A","title":"Dermatology","variant":"variant-a","categoryId":42212,"backgroundColor":null,"image":null,"articles":null,"category":null},{"type":"article-list","condition":null,"color":"#195AA6","title":"Pain","variant":"variant-a","articleIds":[183367,183366,183365],"articles":null}]},{"size":3.5,"blocks":[{"type":"cta","condition":null,"icon":"symbol-bell","color":"#195AA6","title":"Pharmafile Archive","description":"Browse older editions","action":{"type":"url","href":"https://en.calameo.com/subscriptions/6188509","target":"_blank","pwaSubscriptionId":null,"pwaSubscription":null,"optinId":null,"optin":null}},{"type":"ad","title":"Advertisement","advertisementIds":[1974],"adCampaignId":null,"condition":null},{"type":"cta","condition":null,"icon":"symbol-bell","color":"#195AA6","title":"Sign up to our Newsletters","description":"Sign up to our newsletters and digital magazines","action":{"type":"url","href":"https://curwoodcmsltd.formstack.com/forms/samedan","target":"_blank","pwaSubscriptionId":null,"pwaSubscription":null,"optinId":null,"optin":null}},{"type":"guide-install","color":"#195AA6","title":"How to Install","condition":null},{"type":"ad","title":"Advertisement","advertisementIds":[2235],"adCampaignId":null,"condition":null}]}]},"seo":{"home":{"title":"Pharmafile - Therapeutic Areas in focus","description":"Pharma and healthcare legal \u0026 regulatory requirements, financial trends, research, tech, innovation, market insights, analysis, case studies and more","image":"https://cdn.magloft.com/pwa-663/seo/image/9a7a0d77-c45b-4ca4-8317-060aec365417.png","imageAlt":"Pharmafile magazine covers"},"articles":{"title":"Pharmafile Articles","description":"In depth articles covering AI Drug Discovery, Biomarkers, Drug Development, Clinical Trials, Personalised Medicine, Gene Editing, Biosimilars, Market Access, Real World Data, Wearables/ Interventional Devices and Patient Experience","image":"https://cdn.magloft.com/pwa-663/seo/image/a32f5169-eb7c-4073-9c9c-517e7c19e85d.png","imageAlt":"Pharmafile - Articles"},"issues":{"title":"Editions of Pharmafile","description":"Pharmafile includes in depth analysis of therapy areas including: Oncology, Pain Management, Respiratory Diseases, Rare Diseases, Cardiovascular \u0026 Metabolic, Neurological Disorders","image":"https://cdn.magloft.com/pwa-663/seo/image/48839896-f6a6-4404-8744-5e2ef6e70111.png","imageAlt":"Pharmafile - Issues"},"account":{"title":"Pharmafile - Account","description":"Manage your Pharmafile Reader Account...","image":"https://cdn.magloft.com/pwa-663/seo/image/898ff4a9-6db8-47f0-b26b-e2774d221dc2.png","imageAlt":"Reader Account"}},"strings":{"app":{"title":"Pharmafile","subtitle":"Therapeutic areas in focus"},"social":{"facebook":null,"twitter":"https://twitter.com/pharmafocus","linkedin":"https://www.linkedin.com/company/samedan-ltd/","youtube":null,"instagram":null},"topMenu":{"title":null,"subtitle":"Therapeutic areas in focus"},"footerMenu":{"title":"Pharmafile","subtitle":null,"description":null,"email":["info@samedanltd.com"],"privacyUrl":"http://www.samedanltd.com/page/13","termsUrl":"http://www.samedanltd.com/page/13","links":[{"name":"www.samedanltd.com","url":"https://pwa.magloft.com/"}]},"pages":null},"customFonts":[],"phrases":{},"trialEndAt":null,"bypassSubscription":false},"publication":{"id":14881,"title":"Pharmafile","properties":{"subtitle":null,"appIcon":"images/defaults/app-icon.png","promotionalText":null,"companyName":null,"emailReplyTo":"","privacyUrl":null,"termsUrl":null}},"categories":[{"id":42210,"slug":"infectious-diseases","title":"Infectious Diseases","color":"#444444","issueCount":0,"articleCount":4,"categoryGroupIds":[]},{"id":42211,"slug":"rare-diseases","title":"Rare Diseases","color":"#444444","issueCount":0,"articleCount":16,"categoryGroupIds":[]},{"id":42212,"slug":"dermatology","title":"Dermatology","color":"#444444","issueCount":0,"articleCount":6,"categoryGroupIds":[]},{"id":42331,"slug":"oncology","title":"Oncology","color":"#444444","issueCount":0,"articleCount":11,"categoryGroupIds":[]},{"id":42332,"slug":"respiratory","title":"Respiratory","color":"#444444","issueCount":0,"articleCount":4,"categoryGroupIds":[]},{"id":42333,"slug":"pain","title":"Pain","color":"#444444","issueCount":0,"articleCount":3,"categoryGroupIds":[]},{"id":42334,"slug":"neurology","title":"Neurology","color":"#444444","issueCount":0,"articleCount":6,"categoryGroupIds":[]},{"id":42335,"slug":"cardiovascular","title":"Cardiovascular","color":"#444444","issueCount":0,"articleCount":5,"categoryGroupIds":[]},{"id":48101,"slug":"womens-health","title":"Women's Health","color":"#444444","issueCount":0,"articleCount":4,"categoryGroupIds":[]},{"id":42404,"slug":"news","title":"News","color":"#444444","issueCount":0,"articleCount":31,"categoryGroupIds":[]}],"pwaSubscriptions":[],"categoryGroups":[],"slug":"advancing-treatment-options-for-rare-disease-patients","article":{"id":258239,"slug":"advancing-treatment-options-for-rare-disease-patients","issueId":51652,"categoryIds":[42211],"title":"Advancing treatment options for rare disease patients","description":"Chris Moore from Veeva Europe explores how companies are overcoming challenges to develop, launch and educate on new rare disease medicines faster","image":"https://cdn.magloft.com/pdf-import/1066/images/img_22-2.jpg","cover":"https://cdn.magloft.com/publication-14881/screenshots/articles/258239.jpg?ts=1716385578","date":1716332400000,"unlockType":"free","categories":[],"pdfPageId":"cDIuH2VSHrtZ","visible":true,"showOnToc":true,"bookmark":false,"position":19,"publicationId":14881,"pwaOptinId":null,"seoDescription":"Chris moore from veeva europe explores how companies are overcoming challenges to develop, launch and educate on new rare disease medicines faster","classificationIds":[],"pwaSubscriptionIds":[],"source":"typeloft2","trending":false,"html":"\u003cpage-widget padding=\"16 0 24 0\"\u003e\u003cparagraph-widget padding=\"0 24 8 24\"\u003eRARE DISEASES\u003c/paragraph-widget\u003e\u003cheading-widget padding=\"0 24 16 24\" type=\"h2\"\u003e\u003cspan style=\"font-family: \u0026quot;Roboto Slab\u0026quot;;\" class=\"__bold\"\u003eAdvancing treatment options for rare disease patients\u003c/span\u003e\u003c/heading-widget\u003e\u003cparagraph-widget padding=\"8 24 8 24\" background-color=\"rgba(202,45,42,1)\"\u003e\u003cspan class=\"__bold\" style=\"color: rgb(255, 254, 254);\"\u003eChris Moore from Veeva Europe explores how companies are overcoming challenges to develop, launch and educate on new rare disease medicines faster\u003c/span\u003e\u003c/paragraph-widget\u003e\u003cparagraph-widget padding=\"16 24 8 24\"\u003e\u003cspan class=\"__bold\" style=\"color: rgb(38,37,35)\"\u003eThe landscape of rare diseases has evolved significantly and the number of people with a rare disease challenges the very notion of their rarity. Every year, thousands of individuals confront the life-altering reality of being diagnosed with one of the 6,000-8,000 identified rare conditions, collectively affecting one in 17 individuals.\u003cspan class=\"__superscript\"\u003e1\u003c/span\u003e The majority of these conditions are genetic and emerge early in life, with more than half of patients being children, many of whom are not expected to reach their fifth birthday. \u003c/span\u003e\u003c/paragraph-widget\u003e\u003cparagraph-widget padding=\"0 24 8 24\"\u003eLess than 5% of rare diseases have even a single approved treatment today.\u003cspan class=\"__superscript\" style=\"color: rgb(38,37,35)\"\u003e2 \u003c/span\u003eFinding new treatments is an urgent challenge, especially for patients left waiting for medical advancements. Survey findings underscore the long and emotionally taxing journey endured by individuals awaiting a diagnosis. Among adults, a rare disease diagnosis can take up to five years, with half receiving a misdiagnosis. The need for increased awareness, research and expedited treatment pathways in rare disease remains critical.\u003c/paragraph-widget\u003e\u003cparagraph-widget padding=\"0 24 8 24\"\u003eRare diseases challenge traditional ways of doing business. They require the industry to better identify target patient populations for trials and then keep them engaged during the course of the study, even across geographies. Once a medicine is approved, it is crucial to seamlessly transition from trials to treatment given the smaller patient cohort, as the physicians who conduct the trials often become prescribers.\u003c/paragraph-widget\u003e\u003cparagraph-widget padding=\"0 24 8 24\"\u003eThe good news is that the industry is making great progress in how medicines for rare diseases are developed and brought to market. From delivering better site support during clinical studies to greater connectivity between medical and commercial teams, companies are breaking down historic silos and cutting the time to treatment. Along with richer healthcare data and effective medical education for physicians on symptoms and treatment options, these advances will help those undergoing complex patient journeys.\u003c/paragraph-widget\u003e\u003cimage-widget padding=\"8 24 16 24\" aspect-ratio=\"0.7485101311084624\" magnify-label=\"center\" source=\"https://cdn.magloft.com/pdf-import/1066/images/img_22-2.jpg#image/jpeg\"\u003e\u003c/image-widget\u003e\u003cheading-widget padding=\"0 24 16 24\" type=\"h3\"\u003e\u003cspan class=\"__bold\" style=\"color: rgb(38,37,35)\"\u003ePutting the patient experience first during studies \u003c/span\u003e\u003c/heading-widget\u003e\u003cparagraph-widget padding=\"0 24 8 24\"\u003eOver half of orphan drug trials are eventually discontinued or fail to publish results after completion. Often, studies can’t recruit or lead to inconclusive results. When a trial gets off the ground, sites have to invest significant time in keeping a small number of participants engaged. Removing excessive system and process complexity will improve their efforts. For years, sites have voiced their concerns about the multiple disconnected tools they must navigate just to keep a study going. As one site leader explains, navigating unintuitive technology absorbs time from trial activities and can make them feel like they’re asking too much from patients: “The technology shouldn’t be the trial itself, it should support the trial. It’s taking time away from what we want to do, which is taking care of our patients.” Simplifying the technology experience and reducing the admin burden will better meet sites’ and patients’ needs.\u003c/paragraph-widget\u003e\u003cparagraph-widget padding=\"0 24 8 24\"\u003eThe knock-on effects could include better participant retention during rare disease trials. This may widen patient access to life-enhancing new treatments. Reflecting on her own experiences as a rare disease patient, Helen Shaw, co-founder of the virtual site VCTC, observes: “I see how hard it is to take part in a clinical trial. But patients do want that opportunity to be offered something that they wouldn’t get in their standard care, whether additional MRIs or new medicines.”\u003c/paragraph-widget\u003e\u003cheading-widget padding=\"0 24 16 24\" type=\"h3\"\u003e\u003cspan class=\"__bold\" style=\"color: rgb(38,37,35)\"\u003eData insights for effective commercial execution \u003c/span\u003e\u003c/heading-widget\u003e\u003cparagraph-widget padding=\"0 24 8 24\"\u003eData is core to understanding where the greatest patient needs are ahead of a launch. ADVANZ PHARMA is a global biopharma company focused on specialty, hospital and rare disease medicines. Andy Eeckhout, head of CRM and digital solutions for global commercial excellence, explains: “It’s crucial to take a patient perspective. This means using real-time data to understand the patient journey and identify the two or three most influential key opinion leaders (KOLs) per country, so we can best communicate the product across markets.”\u003c/paragraph-widget\u003e\u003cparagraph-widget padding=\"0 24 8 24\"\u003eAn added complexity is that rare diseases often involve multiple specialties. Medical science liaison (MSL) teams have to get up to speed quickly on complex science before meetings with relevant experts, while also being responsible for other (more mainstream) disease areas. “Our customerfacing teams need to be agile communicators and effectively switch to a more patientoriented, in-depth scientific discussion than with generics,” Eeckhout explains. Access to scientific resources and activity data in one place leads to higher-quality conversations. “Pre-call planning is crucial for MSLs before and after launch. The more data they can find, including on past interactions, the better,” Eeckhout adds.\u003c/paragraph-widget\u003e\u003cparagraph-widget padding=\"0 24 8 24\"\u003eDepending on the disease, there could be a long gap before a patient presents with potential symptoms, at which point HCPs will want timely access to experts and resources. Smoother handovers between field medical and sales ensure HCPs can find answers quickly and connect to MSLs if needed. ADVANZ, for example, has launched a pre-launch module in its CRM so that market access, medical and commercial teams can share information compliantly and effectively. Eeckhout notes: “Physicians need a direct line to the industry so they know who to contact when they have questions. Medical and commercial teams need to talk to each other and remain agile across customer conversations.”\u003c/paragraph-widget\u003e\u003cparagraph-widget padding=\"0 24 8 24\"\u003eHighly personalised content for HCPs is also key when targeting diseases with small patient populations. To be effective, marketing teams need clarity on the most impactful content to recommend for field visits across markets. For example, Recordati Rare Disease uses data analytics on its global repository of promotional and medical engagement tools, so it can support content use across a portfolio of 17 rare disease medicines of focus (and a growing global footprint). As its head of marketing and customer engagement, Gordon Daniels, notes: “How we engage with HCPs is critical. We need to know what percentage of our content is being developed and relevant to support different HCPs, whose patients rely on them for their rare disease diagnosis and management.”\u003c/paragraph-widget\u003e\u003cheading-widget padding=\"0 24 16 24\" type=\"h3\"\u003e\u003cspan class=\"__bold\" style=\"color: rgb(38,37,35)\"\u003eDefying the odds, and beating them \u003c/span\u003e\u003c/heading-widget\u003e\u003cparagraph-widget padding=\"0 24 8 24\"\u003eMany scientific advancements are offering hope to rare disease patients and their families. Organisations embarking on this long and sometimes risky trial-to-treatment pathway are making all the difference.\u003c/paragraph-widget\u003e\u003cparagraph-widget padding=\"0 24 8 24\"\u003eCompanies are actively shortening the time to treatment through better support for research sites. This support enables them to concentrate on patient recruitment and retention during trials. Once a drug is approved, integrated technology and comprehensive data can facilitate collaboration between traditionally siloed function. This collaboration allows for the identification, engagement and provision of medical education to relevant HCPs and KOLs.\u003c/paragraph-widget\u003e\u003cparagraph-widget padding=\"0 24 8 24\"\u003eA multifaceted approach is also needed to tackle the diagnostic hurdles faced by patients with rare diseases. This includes raising awareness among healthcare professionals about the signs and symptoms of rare conditions, promoting the use of advanced diagnostic technologies such as genetic testing and molecular imaging and streamlining the referral process for patients suspected of having a rare disease.\u003c/paragraph-widget\u003e\u003cparagraph-widget padding=\"0 24 8 24\"\u003eEfforts can be made to improve access to specialised healthcare services and expertise, particularly in underserved regions where diagnostic and treatment facilities may be limited. Making use of digital platforms can play a pivotal role in connecting patients with rare diseases to specialists, thereby overcoming geographical barriers and facilitating timely diagnosis and intervention.\u003c/paragraph-widget\u003e\u003cparagraph-widget padding=\"0 24 16 24\"\u003eThe journey for every rare disease patient can be a daunting one, with numerous challenges and hurdles they must face. As one biotech leader points out: “Their diagnosis is with them every day. Often, they can’t pronounce the condition, and don’t know anyone else who has it.” It’s up to the life sciences industry to do its part and to help these patients to not just defy the odds, but eventually beat them.\u003c/paragraph-widget\u003e\u003cparagraph-widget padding=\"0 24 24 24\" font-size=\"80\"\u003e\u003cspan class=\"__italic\"\u003eReferences\u003c/span\u003e\u003cbr\u003e\u003col\u003e\u003cli\u003e\u003cspan class=\"__italic\"\u003eVisit: \u003ca class=\"__link\" target=\"_self\" href=\"https://eurordis.org/information-support/what-is-a-rare-disease/\"\u003eeurordis.org/information-support/what-is-a-rare-disease/\u003c/a\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan class=\"__italic\"\u003eVisit: \u003ca class=\"__link\" target=\"_self\" href=\"https://projects.research-and-innovation.ec.europa.eu/en/horizon-magazine/building-blocks-make-rare-diseasetreatments-more-common\"\u003eprojects.research-and-innovation.ec.europa.eu/en/horizon-magazine/building-blocks-make-rare-diseasetreatments-more-common\u003c/a\u003e\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e\u003c/paragraph-widget\u003e\u003ccontainer-widget padding=\"0 24 0 24\"\u003e\u003chorizontal-rule-widget color=\"#f80202\" width=\"6\"\u003e\u003c/horizontal-rule-widget\u003e\u003ccolumns-widget collapse=\"phone\" gutter=\"24\" layout=\"4 8\"\u003e\u003ccolumn-widget\u003e\u003cimage-widget padding=\"8 0 16 0\" aspect-ratio=\"1.0761245674740485\" magnify-label=\"center\" source=\"https://cdn.magloft.com/pdf-import/1066/images/img_23-1.jpg#image/jpeg\"\u003e\u003c/image-widget\u003e\u003c/column-widget\u003e\u003ccolumn-widget\u003e\u003cparagraph-widget padding=\"8 0 8 0\" line-height=\"1.5\" font-size=\"80\"\u003eAs president of \u003cspan class=\"__bold\"\u003eVeeva Europe\u003c/span\u003e, \u003cspan class=\"__bold\"\u003eChris Moore\u003c/span\u003e is responsible for growing the business in the region. A 30+ year veteran of the life sciences industry, Chris started his career at ICI Pharmaceuticals (now AstraZeneca). Chris then joined a startup called Kinesis, building a team delivering document management solutions for pharmaceutical companies. Through a series of mergers and acquisitions, Kinesis ultimately became PwC; Chris was made a partner with PwC in 2001. Chris went on to run both European and US (West Coast) life sciences businesses for IBM before leading the IBM global life sciences consulting Business Analytics and Optimisation unit. Most recently, Chris was the lead partner for life sciences for Europe, the Middle East and Africa at EY. Chris holds a bachelor of science degree in information technology from the University of Salford, UK.\u003c/paragraph-widget\u003e\u003c/column-widget\u003e\u003c/columns-widget\u003e\u003chorizontal-rule-widget color=\"#f80202\" width=\"6\"\u003e\u003c/horizontal-rule-widget\u003e\u003c/container-widget\u003e\u003c/page-widget\u003e","keywordPhrase":"advancing treatment options for rare disease","articleAssets":[{"url":"https://cdn.magloft.com/reader/fonts/roboto-slab.css","extension":"css","contentType":"text/css"},{"url":"https://cdn.magloft.com/pdf-import/1066/images/img_23-1.jpg","extension":"jpeg","contentType":"image/jpeg"},{"url":"https://cdn.magloft.com/reader/fonts/open-sans.css","extension":"css","contentType":"text/css"},{"url":"https://cdn.magloft.com/pdf-import/1066/images/img_22-2.jpg","extension":"jpeg","contentType":"image/jpeg"}]},"publicationId":14881},"__N_SSG":true},"page":"/domains/[domain]/articles/[slug]","query":{"domain":"magazine.pharmafile.com","slug":"advancing-treatment-options-for-rare-disease-patients"},"buildId":"U1LT7ce93wR6IyWFJCllT","isFallback":false,"gsp":true,"scriptLoader":[]}</script></body></html>